(Total Views: 475)
Posted On: 10/01/2024 9:54:10 PM
Post# of 154881
From today filing:
"The results showed Leronlimab inhibited fatty liver development, a key characteristic to early-stage MASH, such that treatment of Humanized NSG mice with Leronlimab caused a three-fold reduction in hepatic steatosis compared to control in an animal of high fructose, high palmitate, high cholesterol diet."
Saw other day on one of the boards, wanting to know steatosis results.
Welp...there it is
"The results showed Leronlimab inhibited fatty liver development, a key characteristic to early-stage MASH, such that treatment of Humanized NSG mice with Leronlimab caused a three-fold reduction in hepatic steatosis compared to control in an animal of high fructose, high palmitate, high cholesterol diet."
Saw other day on one of the boards, wanting to know steatosis results.
Welp...there it is
(6)
(0)
